Stocksigma LogoStocksigma Logo

Cohance Lifesciences Reports Q2FY27 Results and Strategic Updates

Cohance Lifesciences reported consolidated Q2FY27 revenue of ₹4,766 million, up 12.9% QoQ but down 14.2% YoY, with adjusted EBITDA margin recovering to

Cohance Lifesciences Reports Q2FY27 Results and Strategic Updates

Cohance Lifesciences Ltd · Financial Result · 06 Nov 2026, 11:29 pm

Cohance Lifesciences Reports Q2FY27 Results and Strategic Updates Cohance Lifesciences reported consolidated Q2FY27 revenue of ₹4,766 million, up 12.9% QoQ but down 14.2% YoY, with adjusted EBITDA margin recovering to 9.6% (from 2.2% in Q1FY27) and adjusted PAT turning positive at ₹74 million. H1FY27 revenue fell 18.6% YoY to ₹8,989 million. Management expects H2 to be materially stronger across revenue and EBITDA. Separately, the board appointed Dr. Kuber Jagdale as CTO & Executive Director for five years from 7th Nov'26 and approved a 26% equity investment (~₹5.72 crore) in a captive solar-wind SPV.

Original exchange filing (PDF)

More announcements from Cohance Lifesciences Ltd

All Cohance Lifesciences Ltd announcements